ORTEXORTEX News
Tracking DSY? Get live short interest, options flow, and signals on ORTEX.Sign up free →
DS
Trader NoteDSY

Dassault Systèmes shorts ease as stock surges into November earnings

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 28 Oct 2026, 19:18

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

DSY heads into its November 17 earnings with short sellers retreating, borrow costs falling, and the stock up 17% over the past month, a combination that makes the positioning story more interesting than usual.

The lending market has loosened considerably as the rally has gathered pace. Availability has expanded to roughly 498%, meaning nearly five shares are available to borrow for every one already borrowed. That is well above the 52-week low of 135%, and cost to borrow dropped 21% over the week to 0.51%. The borrow market is not flashing any squeeze signal. Separately, the ORTEX short score has fallen sharply, from above 51 in mid-October to 41.9 by October 27. That drop suggests the market is treating the recent rally as genuine re-rating rather than a setup for short sellers to press.

The Street is broadly positive but not aggressively so. The consensus price target sits at EUR 23.40, marginally below the current price of EUR 24.69, which means the analyst community's collective view has been overtaken by the price action. No recent rating changes appear in the data, leaving the target somewhat stale relative to a stock that has added 17% in a month. Among closest peers, SAP gained 5.8% on the week and BSY rose 3.1%, suggesting the European enterprise software complex moved broadly in tandem with DSY. ADBE and ADSK bucked the trend, both falling on the week, a divergence that points to US-listed software facing a different set of headwinds than its European counterparts.

The ownership picture carries one detail worth noting. First Eagle Investment Management added a material 50.9 million shares, bringing its stake to 5.1% of the company, the single largest institutional move in the register. Charles Edelstenne, honorary chairman, remains the largest individual holder at 6.1% and added roughly 116,000 shares in August at prices around EUR 22.80 to EUR 22.97, a level now nearly 8% below the current price. Those purchases were small relative to his existing position, but the direction matters: a senior insider was buying during a period when the stock was depressed. The trade significance score was modest at 3, consistent with a routine accumulation rather than a major statement.

Valuation has re-rated alongside the price. The price-to-book multiple has expanded by 0.46 over the past 30 days to 3.06. The P/E has moved from roughly 15.2 to 17.7 over the same window. Those are meaningful moves in a month, and they push the stock closer to pricing in a recovery rather than simply discounting distress. DSY's earnings yield factor scores in the 64th percentile, suggesting the market still sees reasonable value relative to the software universe, but the headroom has narrowed.

With the Q3 print scheduled for November 17, the main question is whether the past month's re-rating reflects genuine fundamental improvement or a positioning unwind. Short sellers are not pressing hard, borrow is cheap and plentiful, and the consensus price target now sits below the current price. All of this means the next print has less room to simply confirm the move and more pressure to justify it.

Stocks in this article

See the live data behind this article on ORTEX.

Open DSY on ORTEX →

How this article was generated

Generated
28 Oct 2026, 19:22
Data as of
28 Oct 2026, 19:18
Prompt version
v1.0
Data sources
Cost to borrowUtilizationEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
Validation notes
  • soft: missing section mentions: short interest (informational only)

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.